GLENMARK PHARMACEUTICALS LIMITED

The UK Court of Appeal reversed a lower court decision, awarding AstraZeneca an interim injunction against Glenmark's generic dapagliflozin for type II diabetes until the validity hearing judgment.

The UK Court of Appeal has blocked Glenmark Pharmaceuticals from launching its generic version of dapagliflozin until the conclusion of ongoing patent validity proceedings, overturning a previous High Court decision.